Read the current Defeat Diabetes® E-Lerts™ Newsletter

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

 
 
 
     
    
      
       
Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300

Madeira Beach, FL 33708
  

ProtoKinetix Forms Joint Venture Partnership to Launch a Dermatitis Therapeutic Product for the Skin Care Industry

Posted: Wednesday, April 27, 2011

Vancouver, British Columbia, ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market. Over the last 23-years Imaginative Research Associates, Inc. has successfully partnered with several large pharmaceutical dermatology and cosmetic companies and has licensed out patents and know-how to launch many leading products in the skin care arena. Naomi Vishnupad, Ph.D., is the President and COO of this Massachusetts based firm and has over 10-years of experience in the pharmaceutical industry in all areas of drug development.  She has held positions in both big pharma, such as Wyeth Pharmaceuticals and Bristol-Myers Squibb, and small biotech companies.  Naomi holds a Ph.D. and M.S. in immunology and a B.S. in biology.

Upon completion of this formulation, the Joint Venture will be able to offer a topical preparation to specifically address skin conditions caused by inflammation. Conditions such as dermatitis, psoriasis and eczema are often treated with applications of corticosteroids or immune modulators, both of which carry inherent, long term health risks. ProtoKinetix’ AAGP™ has consistently demonstrated powerful anti-inflammatory properties without toxic side effects. The formulation and development of this therapeutic product line will offer hope for an effective prescription and over the counter preparations to combat these chronic inflammation causing diseases, while eliminating potential risks from many of the current front line treatments.

Naomi Vishnupad stated that “There is a great need for new topical anti-inflammatory treatments to treat a wide variety of skin conditions, such as atopic dermatitis, eczema, and psoriasis.  Many of the available treatments have some undesirable side effects, and new therapeutic treatments would be considered an advancement in dermatology”. ProtoKinetix’ President and CEO, Ross Senior comments that “This Joint Venture supports ProtoKinetix’ pursuit of AAGP™ products for markets looking for safe and effective solutions to diseases and conditions caused by chronic inflammation and immune response deficiencies”.

About ProtoKinetix, Inc.

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX’s primary focus is on the therapeutic potential for AAGP™ in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.


The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior –   President and CEO

Company Office:                       Investor Contact:
2225 Folkestone Way                   ProtoKinetix Inc.
West Vancouver, BC V7S 2Y6        604-926-6627
 

 
 
 
 
 
Join us on Facebook
 
 
 

Send your unopened, unexpired diabetes testing supplies to:

Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708

 

DDF advertisement
 

 Friendly Banner
 


Friendly Banner
 
 
 
Analyze nutrition content by portion
DDF advertisement